ArticleJournal of translational medicine2026
Histone lactylation boosted SET8 potentiates carcinogenesis and angiogenesis of pancreatic ductal adenocarcinoma by cooperating with MTA1/NuRD complex.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe pathophysiological role of lysine methyltransferase SET domain-containing protein 8 (SET8) in pancreatic ductal adenocarcinoma (PDAC) remains poorly understood. Emerging evidence suggests that histone lactylation, a novel post-translational modification, may influence tumor progression. However, the interplay between SET8 and lactate metabolism in PDAC pathogenesis has not been elucidated.
methodsImmunohistochemical staining and bioinformatics analysis of clinical databases were performed to evaluate SET8 expression and its prognostic relevance in PDAC. Affinity purification coupled with mass spectrometry (MS), co-immunoprecipitation (Co-IP), and glutathione S-transferase (GST) pull-down assays were conducted to identify interactions between SET8 and the MTA1/NuRD complex. Functional roles of the SET8/MTA1/NuRD complex were assessed using chromatin immunoprecipitation (ChIP)-seq, RT-qPCR, western blot, wound healing, transwell invasion, endothelial tube formation, in vivo Chicken Yolk Sac Membrane (YSM) assays, and Masson staining.
resultsSET8 expression was significantly upregulated in PDAC and correlated with poor prognosis. SET8 physically interacted with the MTA1/NuRD complex via direct binding to MTA1, as confirmed by Co-IP and GST pull-down assays. The SET8/MTA1/NuRD complex repressed tumor suppressor genes, including SOCS2, through chromatin remodeling. Depletion of SET8 or MTA1 reduced tumorigenesis, angiogenesis, and metastasis. Overexpression of SET8 promoted oncogenic phenotypes in an MTA1-dependent manner. Mechanistically, lactate dehydrogenase A (LDHA)-mediated histone lactylation drove SET8 expression, linking metabolic reprogramming to epigenetic dysregulation.
conclusionsThis study identifies SET8 as a proto-oncogene in PDAC, whose expression is regulated by histone lactylation. The SET8/MTA1/NuRD complex facilitates tumor progression by epigenetically silencing SOCS2, highlighting a crosstalk between histone methylation and deacetylation. Targeting the lactylation-SET8/MTA1/NuRD axis may offer a novel therapeutic strategy for PDAC, particularly by restoring SOCS2-mediated tumor suppression. These findings deepen our understanding of metabolic-epigenetic interplay in cancer and provide actionable insights for clinical intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.